|
Recorded Presentation from the NCCN Pharmacy Updates: Hematopoietic Cell Transplantation - An Overview of Hematopoietic Cell Mobilization |
1.00 |
08/12/2024 - 12:00am to 08/12/2025 - 12:00am |
|
Recorded Presentation from the NCCN Pharmacy Updates: Navigating the Challenging Treatment Landscape for HIV-Associated, Non-AIDS Defining Cancers |
1.00 |
08/12/2024 - 12:00am to 08/12/2025 - 12:00am |
|
Renal Cell Carcinoma: Evolving Perspectives on Optimal Treatment |
1.00 |
08/30/2024 - 12:00am to 08/30/2025 - 12:00am |
|
Recorded Presentation from the NCCN Pharmacy Updates: What Grade Are You In? The Role of Targeted Therapy in Pediatric Diffuse High-Grade Gliomas |
1.00 |
09/10/2024 - 12:00am to 09/10/2025 - 12:00am |
|
Archived NCCN Tumor Boards: The Role of Molecular Profiling in the Management of Uterine Cancer |
1.00 |
09/10/2024 - 12:00am to 09/10/2025 - 12:00am |
|
NCCN Guidelines® Insights - Colorectal Cancer Screening, Version 1.2024 |
1.00 |
09/10/2024 - 12:00am to 09/10/2025 - 12:00am |
|
Recorded Presentation from the NCCN Pharmacy Updates: Updates in the Treatment of Kidney Cancer |
1.00 |
10/03/2024 - 12:00am to 10/03/2025 - 12:00am |
|
NCCN Guidelines® Insights - Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024 |
1.00 |
10/10/2024 - 12:00am to 10/10/2025 - 12:00am |
|
Archived NCCN Tumor Boards: Immune Checkpoint Inhibitors for First-Line Therapy in Esophagogastric/Esophagogastric Junction Cancer |
1.00 |
10/28/2024 - 12:00am to 10/28/2025 - 12:00am |
|
Recorded Presentation from the NCCN Pharmacy Updates: Novel Therapies for Treating ESR1 and RET-Fusion Mutations in Breast Cancer |
1.00 |
11/01/2024 - 12:00am to 11/01/2025 - 12:00am |
|
NCCN Guidelines® Insights - Management of Immunotherapy-Related Toxicities, Version 2.2024 |
1.00 |
11/10/2024 - 12:00am to 11/10/2025 - 12:00am |
|
Recorded Presentation from the NCCN Pharmacy Updates: Chemoimmunotherapy Updates in Advanced/Metastatic Non-Small Cell Lung Cancer |
1.00 |
11/12/2024 - 12:00am to 11/12/2025 - 12:00am |
|
NCCN Tumor Boards: T-Cell Engager Therapy for Diffuse Large B-Cell Lymphoma: Bispecific Antibodies for Relapsed/Refractory Disease |
1.00 |
11/14/2024 - 12:00am to 07/13/2025 - 12:00am |
|
Archived NCCN Tumor Boards: Multidisciplinary Management of Head and Neck Cancers |
1.00 |
11/26/2024 - 12:00am to 11/26/2025 - 12:00am |
|
Archived NCCN Tumor Boards: New Approaches to Treatment of Bladder Cancer |
1.00 |
11/26/2024 - 12:00am to 11/26/2025 - 12:00am |
Facebook
Twitter
LinkedIn
Forward